Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Company Announcement - Cogent Biosciences, Inc. will participate in a fireside chat at the Leerink Healthcare Conference on March 12, 2025, at 10:00 a.m. ET [1] - A live webcast of the event will be available on the Investors & Media page of Cogent's website, with a replay accessible approximately two hours after the event and archived for up to 30 days [2] Inducement Grant - The Compensation Committee of Cogent's Board of Directors approved an "inducement" equity award for a new employee on March 4, 2025, under the company's 2020 Inducement Plan [3] - The award consists of a nonqualified option to purchase 90,000 shares of Cogent common stock, with a 10-year term and an exercise price equal to the closing price on the grant date [3] - The vesting schedule includes 25% vesting on the 1-year anniversary of the grant date, with the remainder vesting in equal monthly installments over the subsequent 36 months, contingent on the employee's continued employment [3] Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing a portfolio of targeted therapies for mutations in ErbB2, PI3Kα, and KRAS [4] - Cogent is headquartered in Waltham, MA, and Boulder, CO, and provides updates and important information for investors on its website and social media platforms [4]